Skip to main content
    B

    Boston Scientific Corp (BSX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $43.70
    -0.64 (-1.44%)

    Market Cap: $64.27B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Boston Scientific Corp (BSX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Boston Scientific (BSX) to earn $3.17 per share in the fiscal year ending Dec 31, 2026, on revenue of $20.97B. Of 31 analysts, 20 rate the stock Buy or Strong Buy, 11 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $3.13.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 31 ratings average 2.16, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 65% of the ratings.

    RatingAnalystsShare
    Strong Buy619.4%
    Buy1445.2%
    Hold1135.5%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    31

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus falls 1.3% and revenue estimates fall 0.4%.

    Fiscal year ending Dec 31, 2026
    $3.17
    EPS consensus, revenue $20.97B
    Fiscal year ending Dec 31, 2027
    $3.13
    EPS consensus, revenue $20.88B
    Next report
    Feb 2, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$3.17$3.15 to $3.2928$20.97B$20.90B to $21.10B28
    Dec 31, 2027$3.13$3.02 to $3.4528$20.88B$20.44B to $22.50B28

    Quarterly Estimates

    The EPS consensus falls from $0.78 for the quarter ending Dec 31, 2026 to $0.74 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.78$0.74 to $0.8326$5.23B$5.04B to $5.51B26
    Mar 31, 2027$0.74$0.70 to $0.7816$5.06B$4.94B to $5.14B15

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 0 upward and 36 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 2027026
    Quarter ending Mar 31, 2027010

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 3.9% from $3.30.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$3.17$3.17$3.25$3.29$3.30-4.0%
    Fiscal year ending Dec 31, 2027$3.13$3.13$3.38$3.43$3.44-9.0%
    Quarter ending Mar 31, 2027$0.74$0.80$0.80$0.80$0.80-7.2%

    Frequently Asked Questions About BSX

    What is the BSX stock forecast?

    Consensus analyst estimates put Boston Scientific's EPS at $3.17 for the fiscal year ending Dec 31, 2026, on revenue of $20.97B. The consensus rating from 31 analysts is Buy.

    How do analysts rate BSX stock?

    Of 31 analysts covering Boston Scientific, 6 rate it Strong Buy, 14 Buy, 11 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from BSX next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $3.17, with estimates from $3.15 to $3.29 from 28 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $3.13, with estimates from $3.02 to $3.45 from 28 analysts.

    What revenue do analysts expect from Boston Scientific next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $20.97B, with estimates from $20.90B to $21.10B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $20.88B, with estimates from $20.44B to $22.50B.

    How many analysts cover BSX?

    31 analysts rate Boston Scientific stock, and 28 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.